 | Up a level |
Journal Article
Andreadis, C., Tam, C. S., Borchmann, P., Jaeger, U., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S., Bishop, M. R., Foley, S. R., Westin, J. R., Fleury, I, Ho, P. J., Mielke, S., Teshima, T., Salles, G. A., Schuster, S. J., Bachanova, V, Maziarz, R. T., Besien, K., V, Izutsu, K., Wagner-Johnston, N. D., Kato, K., Corradini, P., Tiwari, R., Awasthi, R., Lawniczek, T., Eldjerou, L. K. and Kersten, M. J. (2020). Correlation of Bridging Therapy (BT) and Lymphodepleting Chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel. Oncol. Res. Treat., 43 (SUPPL 4). S. 62 - 64. BASEL: KARGER. ISSN 2296-5262
Balke-Want, H. and Borchmann, P. (2021). CAR T-cell therapy for malignant B-cell lymphoma A new treatment paradigm. Internist, 62 (6). S. 589 - 597. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289
Behringer, K., Goergen, H., Borchmann, P., Diehl, V., Fuchs, M., Lohri, A., Hitz, F., Zijlstra, J. M., Greil, R., Markova, J., Topp, M. S., Soekler, M., Mathas, S., Meissner, J., von Tresckow, B., Boell, B. and Engert, A. (2014). IMPACT OF BLEOMYCIN AND DACARBAZINE WITHIN THE ABVD REGIMEN IN THE TREATMENT OF EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE GHSG HD13 TRIAL. Haematologica, 99. S. 497 - 498. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Behringer, K., Halbsguth, T. V. and Borchmann, P. (2014). Late sequelae and survivorship following treatment of Hodgkin's lymphoma. Onkologe, 20 (5). S. 470 - 477. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415
Behringer, K., Oertel, M., Rueffer, J. U. and Borchmann, P. (2022). Disease- and treatment-related late sequelae in Hodgkin lymphoma. Onkologie, 28 (10). S. 914 - 923. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234
Behringer, K., Thielen, I., Mueller, H., Goergen, H., Eibl, A. D., Rosenbrock, J., Halbsguth, T., Eichenauer, D. A., Fuchs, M., Reiners, K. S., Renno, J. H., van der Ven, K., Kuehr, M., von Wolff, M., Diehl, V., Engert, A. and Borchmann, P. (2020). Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial (vol 23, pg 1818, 2012). Ann. Oncol., 31 (8). S. 1093 - 1094. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Behringer, K., Wildt, L., Mueller, H., Mattle, V., Ganitis, P., van den Hoonaard, B., Ott, H. W., Hofer, S., Pluetschow, A., Diehl, V., Engert, A. and Borchmann, P. (2010). No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann. Oncol., 21 (10). S. 2052 - 2061. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., Morschhauser, F., Janz, M., Flinn, I, Rabitsch, W., Kwong, Y-L, Kersten, M. J., Minnema, M. C., Holte, H., Chan, E. H. L., Martinez-Lopez, J., Mueller, A. M. S., Maziarz, R. T., McGuirk, J. P., Bachy, E., Le Gouill, S., Dreyling, M., Harigae, H., Bond, D., Andreadis, C., McSweeney, P., Kharfan-Dabaja, M., Newsome, S., Degtyarev, E., Awasthi, R., del Corral, C., Andreola, G., Masood, A., Schuster, S. J., Jaeger, U., Borchmann, P. and Westin, J. R. (2022). Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N. Engl. J. Med., 386 (7). S. 629 - 640. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406
Boell, B., Pluetschow, A., Eichenauer, D., von Tresckow, B., Atta, J., Pfreundschuh, M., Michaela, F. B., Vogelhuber, M., Soekler, M., Fuchs, M., Engert, A. and Borchmann, P. (2015). GERMAN HODGKIN STUDY GROUP PHASE I TRIAL OF DOXORUBICIN, VINBLASTINE, DACARBAZINE, AND LENALIDOMIDE (AVD-REV) FOR ELDERLY HODGKIN LYMPHOMA PATIENTS-FINAL ANALYSIS. Haematologica, 100. S. 322 - 323. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Boell, B., Pluetschow, A., Eichenauer, D. A., Thielen, I, von Tresckow, B., Atta, J., Pfreundschuh, M., Feuring-Buske, M., Vogelhuber, M., Soekler, M., Fuchs, M., Engert, A. and Borchmann, P. (2014). German Hodgkin Study Group Phase I trial of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) for elderly Hodgkin Lymphoma patients. Oncol. Res. Treat., 37. S. 12 - 13. BASEL: KARGER. ISSN 2296-5262
Borchmann, P. (2016). Development of chimeric antigen receptor (CAR) T-cell immunotherapy. Oncol. Res. Treat., 39. S. 27 - 28. BASEL: KARGER. ISSN 2296-5262
Borchmann, P. (2016). PET guided therapy of Hodgkin Lymphoma. Oncol. Res. Treat., 39. S. 40 - 41. BASEL: KARGER. ISSN 2296-5262
Borchmann, P., Eichenauer, D., Pluetschow, A., Kreissl, S., Fuchs, M., Soekler, M., Engel, N., Mathas, S., Behringer, K., Kobe, C., Dietlein, M., Diehl, V. and Engert, A. (2014). TARGETED BEACOPP VARIANTS IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS OF A RANDOMIZED PHASE II STUDY. Haematologica, 99. S. 497 - 499. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Borchmann, P., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Zijlstra, J. M., Huettmann, A., Markova, J., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M. and Engert, A. (2017). TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 24 - 26. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Borchmann, P., Juehling, A., Goedel, P., Balke-Want, H., Schmid, C., Ayuk, F., Holtkamp, S., Preussner, L., Zadoyan, G., Hanssens, L., Kaiser, A., Jurk, M., Buerger, I, Schneider, D., Dropulic, B., Overstijns, T., Holtick, U., Scheid, C., Miltenyi, S. and Hallek, M. (2020). Phase I trial of MB-CART2019.1, a novel CD20 and CD19 targeting tandem chimeric antigen receptor, in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma. Oncol. Res. Treat., 43 (SUPPL 4). S. 56 - 57. BASEL: KARGER. ISSN 2296-5262
Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M. and Engert, A. (2020). Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 32 - 33. BASEL: KARGER. ISSN 2296-5262
Borchmann, P., Tam, C. S., Jaeger, U., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S. M., Bishop, M. R., Andreadis, C., Foley, S. R., Westin, J. R., Fleury, I., Ho, P. J., Mielke, S., Salles, G., Maziarz, R. T., Anak, Oe, Pacaud, L. B., del Corral, C., Awasthi, R., Agoulnik, S., Tai, F. and Schuster, S. J. (2018). An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Oncol. Res. Treat., 41. S. 36 - 38. BASEL: KARGER. ISSN 2296-5262
Borchmann, P., Viardot, A., Wermke, M., Subklewe, M., Siddiqi, T., Jaeger, U., Hasskarl, J. and Abramson, J. S. (2018). Results of the phase I transcend NHL 001 trial of JCAR017 support the phase II transcend world study of this Chimeric Antigen Receptor (CAR) T-Cell therapy in patients (Pts) with aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL). Oncol. Res. Treat., 41. S. 37 - 38. BASEL: KARGER. ISSN 2296-5262
Borchmann, S., Mueller, H., Haverkamp, H., Baues, C., Markova, J., Huettmann, A., Glunz, A., Fuchs, M., Borchmann, P. and Engert, A. (2016). OSTEONECROSIS AFTER TREATMENT FOR HODGKIN LYMPHOMA: THE GERMAN HODGKIN STUDY GROUP EXPERIENCE. Haematologica, 101. S. 62 - 63. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Borchmann, S., Mueller, H., Hude, I, Fuchs, M., Borchmann, P. and Engert, A. (2019). Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials. Ann. Oncol., 30 (8). S. 1329 - 1335. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Broeckelmann, P., Goergen, H., Fuchs, M., Eich, H., Stein, H., Diehl, V., Borchmann, P. and Engert, A. (2015). Sources of Errors in the Staging of Hodgkin Lymphoma - An Analysis of the central Assessment of diagnostic Measures 5965 Patients of the German Hodgkin Study Group (GHSG). Internist, 56. S. 3 - 5. NEW YORK: SPRINGER. ISSN 1432-1289
Broeckelmann, P., Goergen, H., Fuchs, M., Eich, H., Stein, H., Diehl, V., Borchmann, P. and Engert, A. (2015). Sources of Errors in the Staging of Hodgkin Lymphoma - An Analysis of the central Assessment of diagnostic Measures 5965 Patients of the German Hodgkin Study Group (GHSG). Internist, 56. S. 3 - 5. NEW YORK: SPRINGER. ISSN 1432-1289
Broeckelmann, P. J., Goergen, H., Fuchs, M., Eich, H. T., Stein, H., Diehl, V., Borchmann, P. and Engert, A. (2016). Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: Experience of the German Hodgkin Study Group (GHSG). Oncol. Res. Treat., 39. S. 122 - 123. BASEL: KARGER. ISSN 2296-5262
Broeckelmann, P. J., Goergen, H., Kohnhorst, C., Fuchs, M., Borchmann, P. and Engert, A. (2016). VERY LATE RELAPSE > 5 YEARS AFTER FIRST DIAGNOSIS OF HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP HD7-HD12 TRIALS. Haematologica, 101. S. 46 - 48. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Broeckelmann, P. J., Goergen, H., Kohnhorst, C., Fuchs, M., Borchmann, P. and Engert, A. (2016). VERY LATE RELAPSE > 5 YEARS AFTER FIRST DIAGNOSIS OF HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP HD7-HD12 TRIALS. Haematologica, 101. S. 320 - 321. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Broeckelmann, P. J., Goergen, H., Pluetschow, A., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE HODGKIN LYMPHOMA (HL): UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7, HD8, HD10 AND HD11 TRIALS. Haematologica, 101. S. 4 - 5. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Broeckelmann, P. J., Mueller, H., Casasnovas, O., Hutchings, M., von Tresckow, B., Jurgens, M., McCall, S. J., Morschhauser, F., Fuchs, M., Borchmann, P., Moskowitz, C. H. and Engert, A. (2017). Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann. Oncol., 28 (6). S. 1352 - 1359. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Buerkle, C., Goergen, H., Mueller, H., Broeckelmann, P., Kreissl, S., Fuchs, M., Engert, A., Borchmann, P. and Behringer, K. (2016). PATIENT PREFERENCES - SURVEY OF HODGKIN LYMPHOMA SURVIVORS ON TREATMENT-ASSOCIATED BURDEN AND SIDE EFFECTS. Haematologica, 101. S. 146 - 148. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Buerkle, C., Goergen, H., Mueller, H., Broeckelmann, P. J., Kreissl, S., Fuchs, M., Engert, A., Borchmann, P. and Behringer, K. (2016). PATIENT PREFERENCES - SURVEY OF HL SURVIVORS ON TREATMENT-ASSOCIATED BURDENS AND SIDE EFFECTS. Haematologica, 101. S. 61 - 62. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Eich, H. T., Kriz, J., Klimm, B., Sasse, S., Goergen, H., Diehl, V., Borchmann, P., Mueller, R. and Engert, A. (2012). Involved-field (IF) Versus Extended-field (EF) Radiation Therapy (RT) for Patients in Early Unfavorable Stages of Hodgkin Lymphoma: 10-year Update of the HD8 Trial of the German Hodgkin Study Group (GHSG). Int. J. Radiat. Oncol. Biol. Phys., 84 (3). S. S70 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0360-3016
Eichenauer, D. A., Goergen, H., Pluetschow, A., Wongso, D., Behringer, K., Kreissl, S., Thielen, I., Halbsguth, T., Broeckelmann, P. J., Fuchs, M., Boell, B., von Tresckow, B., Borchmann, P. and Engert, A. (2016). Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. Leukemia, 30 (6). S. 1425 - 1429. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Eichenauer, D. A., Kreissl, S., Buehnen, I., Baues, C., Kobe, C., van Heek, L., Goergen, H., Fuchs, M., Hartmann, S., von Tresckow, B., Engert, A. and Borchmann, P. (2021). PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study. Ann. Oncol., 32 (6). S. 807 - 811. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Eichenauer, D. A., Kreissl, S., Buehnen, I., Goergen, H., Hartmann, S., Fuchs, M., von Tresckow, B., Engert, A. and Borchmann, P. (2020). PET-2-guided escalated BEACOPP for patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 87 - 89. BASEL: KARGER. ISSN 2296-5262
Eichenauer, D. A., Pluetschow, A., Fuchs, M., von Tresckow, B., Borchmann, P. and Engert, A. (2017). Long-term outcome of patients with early-stage nodular lymphocyte-predominant hodgkin lymphoma (NLPHL) treated within the randomized HD7, HD10 and HD13 trials: An analysis from the German Hodgkin Study Group (GHSG). Oncol. Res. Treat., 40. S. 142 - 143. BASEL: KARGER. ISSN 2296-5262
Eichenauer, D. A., Pluetschow, A., Fuchs, M., von Tresckow, B., Diehl, V., Borchmann, P. and Engert, A. (2017). LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA TREATED WITHIN THE RANDOMIZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 82 - 83. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Ferdinandus, J., Oertel, M., Eichenauer, D. A., Meissner, J., Engert, A. and Borchmann, P. (2022). Advanced-stage Hodgkin lymphoma. Onkologie, 28 (10). S. 889 - 901. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234
Frontzek, F., Ziepert, M., Nickelsen, M., Altmann, B., Glass, B., Haenel, M., Truemper, L., Held, G., Bentz, M., Borchmann, P., Dreyling, M., Viardot, A., Kroschinsky, F., Metzner, B., Staiger, A. M., Horn, H., Ott, G., Rosenwald, A., Loeffler, M., Lenz, G. and Schmitz, N. (2020). 10-year follow-up of the R-MegaCHOEP trial: conditional survival analysis reveals 1-year progression-free survival as crucial prognostic factor for long-term outcome in young high-risk patients with aggressive B-cell lymphoma. Oncol. Res. Treat., 43 (SUPPL 4). S. 64 - 65. BASEL: KARGER. ISSN 2296-5262
Fuchs, M., Wongso, D., Pluetschow, A., Feuring-Buske, M., Hertenstein, B., Hoeffkes, H. -G, Vogelhuber, M., von Tresckow, B., Biersack, H., Link, H., Topp, M. S., Fischer, N., Bredenfeld, H., Sasse, S., Behringer, K., Boell, B., Borchmann, P. and Engert, A. (2014). Final analysis of a randomized phase II trial with prednisone, vinblastine, doxorubicin, and gemcitabine in patients with early unfavorable Hodgkin lymphoma -PVAG-14 pilot-. Oncol. Res. Treat., 37. S. 11 - 12. BASEL: KARGER. ISSN 2296-5262
Fuchs, M., Wongso, D., Pluetschow, A., Feuring-Buske, M., Hertenstein, B., Hoeffkes, H. G., Vogelhuber, M., von Tresckow, B., Biersack, H., Link, H., Topp, M. S., Fischer, N., Bredenfeld, H., Sasse, S., Behringer, K., Boell, B., Borchmann, P. and Engert, A. (2014). FINAL ANALYSIS OF A RANDOMIZED PHASE II STUDY WITH PREDNISONE, VINBLASTINE, DOXORUBICIN, AND GEMCITABINE IN PATIENTS WITH EARLY UNFAVORABLE HODGKIN LYMPHOMA -PVAG-14 PILOT-. Haematologica, 99. S. 497 - 498. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Gillessen, S., Pluetschow, A., Fuchs, M., Markova, J., Greil, R., Topp, M., Meissner, J., Zijlstra, J., Eichenauer, D., Broeckelmann, P., Diehl, V., Borchmann, P., Engert, A. and von Tresckow, B. (2020). Dose-Intensification in early unfavorable Hodgkin Lymphoma: Long-Term Follow up of the randomized German Hodgkin Study Group (GHSG) HD14 trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 88 - 90. BASEL: KARGER. ISSN 2296-5262
Haanen, J., Mackensen, A., Koenecke, C., Alsdorf, W., Desuki, A., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Wiegert, E., Schulz, C., Rengstl, B., Preussner, L., Tuereci, O. and Sahin, U. (2021). BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+advanced solid tumors. Ann. Oncol., 32. S. S1392 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Hay, A. E., Klimm, B., Chen, B. E., Goergen, H., Shepherd, L. E., Fuchs, M., Gospodarowicz, M. K., Borchmann, P., Connors, J. M., Markova, J., Crump, M., Lohri, A., Winter, J. N., Doerken, B., Pearcey, R. G., Diehl, V., Horning, S. J., Eich, H. T., Engert, A. and Meyer, R. M. (2013). An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann. Oncol., 24 (12). S. 3065 - 3070. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Hoechsmann, B., Leichtle, R., Roeth, A., Haferlach, T., Hilgendorf, I, Schmidt, B., Mohm, J., Schaedlich, B., Borchmann, P., Mueller, M. and Schrezenmeier, H. (2014). Management of pregnancies in paroxysmal nocturnal hemoglobinuria (PNH) patients: A report of 10 German cases of the international PNH patient registry. Oncol. Res. Treat., 37. S. 244 - 246. BASEL: KARGER. ISSN 2296-5262
Hoechsmann, B., Leichtle, R., Roeth, A., Panse, J., Haferlach, T., Borchmann, P., Aulitzky, W. E., Dengler, J., Port, M., Platzbecker, U., Klausmann, M., Steinmetz, T., Becker, M., Schmidt, B. and Schrezenmeier, H. (2015). Data from German centers in the global PNH Patient Registry-analysis of the translation of the DGHO-guidelines for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in real life therapy. Oncol. Res. Treat., 38. S. 105 - 107. BASEL: KARGER. ISSN 2296-5262
Hude, I., Mueller, H., Goergen, H., Buerkle, C., Behringer, K., Diehl, V., Engert, A. and Borchmann, P. (2016). LONGITUDINAL EVALUATION OF HEALTH-RELATED QUALITY OF LIFE IN HODGKIN LYMPHOMA PATIENTS AND SURVIVORS: RESULTS FROM THE GERMAN HODGKIN STUDY GROUP. Haematologica, 101. S. 62 - 63. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Jakob, T., Follmann, M., Borchmann, P., Baues, C., Sasse, S., Broeckelmann, P. J., Kreissl, S., Eichenauer, D., von Tresckow, B., Buerkle, C., Engert, A. and Skoetz, N. (2018). Guideline update on diagnosis, therapy and follow-up of adult Hodgkin lymphoma patients. Oncol. Res. Treat., 41. S. 17 - 18. BASEL: KARGER. ISSN 2296-5262
Klimm, B., Goergen, H., Fuchs, M., von Tresckow, B., Boell, B., Meissner, J., Glunz, A., Diehl, V., Eich, H. T., Engert, A. and Borchmann, P. (2013). Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Ann. Oncol., 24 (12). S. 3070 - 3077. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Kobe, C., Dietlein, M., Borchmann, P., Engert, A., Kuhnert, G., Fuchs, M., Haverkamp, H., Eich, H. T., Kriz, J. and Diehl, V. (2011). PET-Response Adapted Therapy in Hodgkin Lymphoma. Eur. J. Cancer, 47. S. S16 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 0959-8049
Kobe, C., Goergen, H., Fuchs, M., Eich, H. T., Baues, C., Diehl, V., Kuhnert, G., Drzezga, A., Dietlein, M., Engert, A. and Borchmann, P. (2017). Treatment Reduction in Patients with Advanced-Stage Hodgkin Lymphoma and Negative Interim FDG-PET: Final Results of the International, Randomized, Phase 3 HD18 Trial by the German Hodgkin Study Group. Eur. J. Nucl. Med. Mol. Imaging, 44. S. S312 - 1. NEW YORK: SPRINGER. ISSN 1619-7089
Kobe, C., Kuhnert, G., Haverkamp, H., Fuchs, M., Kahraman, D., Eich, H. -T., Kriz, J., Baues, C., Nast-Kolb, B., Broeckelmann, P. J., Borchmann, P., Drzezga, A., Engert, A. and Dietlein, M. (2015). Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma. Nuklearmedizin, 54 (6). S. 241 - 247. STUTTGART: GEORG THIEME VERLAG KG. ISSN 2567-6407
Kreissl, S., Buerkle, C., Ruffer, U., Mehnert, A. and Borchmann, P. (2018). Cancer-related fatigue in Hodgkin's lymphoma. Onkologe, 24 (4). S. 329 - 335. NEW YORK: SPRINGER. ISSN 1433-0415
Kreissl, S., Eichenauer, D. and Borchmann, P. (2014). New developments in the treatment of advanced Hodgkin's lymphoma. Onkologe, 20 (5). S. 457 - 463. NEW YORK: SPRINGER. ISSN 1433-0415
Kreissl, S., Eichenauer, D. A., Meissner, J., Topp, M. S., Engert, A. and Borchmann, P. (2018). New developments in the treatment of advanced classical Hodgkin's lymphoma. Onkologe, 24 (4). S. 315 - 322. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415
Kreissl, S., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Huettmann, A., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M., Engert, A. and Borchmann, P. (2017). Treatment reduction in patients with advanced-stage-Hodgkin-lymphoma and negative interim PET: final results of the international randomized phase 3 trial HD18 by the German Hodgkin Study Goup. Oncol. Res. Treat., 40. S. 201 - 202. BASEL: KARGER. ISSN 2296-5262
Mackensen, A., Haanen, J. B. A. G., Koenecke, C., Alsdorf, W., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Bokemeyer, C., Klobuch, S., Smit, E., Mueller, F., Desuki, A., Lueke, F., Wiegert, E., Flemmig, C., Schulz-Eying, C., Rengstl, B., Preussner, L., Tuereci, O. and Sahin, U. (2022). BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours. Ann. Oncol., 33 (7). S. S1404 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Momotow, J., Sasse, S., Pluetschow, A., Huettmann, A., Basara, N., Koenecke, C., Martin, S., Bentz, M., Grosse-Thie, C., Thorspecken, S., de Wit, M., Kobe, C., Dietlein, M., von Tresckow, B., Fuchs, M., Borchmann, P. and Engert, A. (2020). AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 89 - 90. BASEL: KARGER. ISSN 2296-5262
Murawski, N., Poeschel, V., Ziepert, M., Altmann, B., Dreyling, M., Borchmann, P., Viardot, A., Luminari, S., Witzens-Harig, M., Dierlamm, J., Haenel, M., Truemper, L., Metzner, B., Lengfelder, E., Keller, U., Ruebe, C., Berdel, C., Schmitz, N., Held, G. and Pfreundschuh, M. (2018). Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. Oncol. Res. Treat., 41. S. 238 - 239. BASEL: KARGER. ISSN 2296-5262
Prinz, J., Goedel, P., Shimabukuro-Vornhagen, A., Kochanek, M., Borchmann, P. and Boell, B. (2018). Immune-related toxicity syndromes in patients treated with chimeric antigen receptor T cell. Med. Klin.-Intensivmed Notfallmed., 113 (4). S. 329 - 331. NEW YORK: SPRINGER. ISSN 2193-6218
Prinz, J., Goedel, P., Shimabukuro-Vornhagen, A., von Bergwelt-Baildon, M., Kochanek, M., Borchmann, P. and Boell, B. (2018). Immune-related toxicity syndromes in patients treated with chimeric antigen receptor T cell therapy. Oncol. Res. Treat., 41. S. 87 - 88. BASEL: KARGER. ISSN 2296-5262
Sasse, S., Broeckelmann, P. J., Goergen, H., Pluetschow, A., Mueller, H., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7 AND HD10 TRIAL. Haematologica, 101. S. 12 - 13. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Sasse, S., Broeckelmann, P. J., Goergen, H., Pluetschow, A., Mueller, H., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD8 AND HD11 TRIAL. Haematologica, 101. S. 13 - 15. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Sasse, S., Klimm, B., Goergen, H., Fuchs, M., Heyden-Honerkamp, A., Lohri, A., Koch, O., Wilhelm, M., Trenn, G., Finke, J., Mueller, R. P., Diehl, V., Eich, H. T., Borchmann, P. and Engert, A. (2012). Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann. Oncol., 23 (11). S. 2953 - 2960. OXFORD: OXFORD UNIV PRESS. ISSN 0923-7534
Schuster, S. J., Bishop, M. R., Tam, C., Waller, E. K., Borchmann, P., McGuirk, J., Jaeger, U., Jaglowski, S., Andreadis, C., Westin, J., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Anak, O., Pacaud, L., Awasthi, R., Tai, F., Salles, G. and Maziarz, R. T. (2017). GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - AN INTERIM ANALYSIS. Haematologica, 102. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Sickinger, M. T., von Tresckow, B., Kobe, C., Engert, A., Borchmann, P. and Skoetz, N. (2014). PET-ADAPTED TREATMENT MODIFICATION IN EARLY STAGE HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Haematologica, 99. S. 399 - 400. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Thurner, L., Held, G., Poeschel, V, Berdel, C., Ott, G., Schmidt, C., Viardot, A., Engel-Riedel, W., Borchmann, P., Shpilberg, O., Witzens-Harig, M., Frickhofen, N., Nickelsen, M., Griesinger, F., Krammer-Steiner, B., Neubauer, A., Federico, M., Brown, de Nully P., Stilgenbauer, S., Murawski, N., Altmann, B., Truemper, L., Schmidberger, H., Ruebe, C., Fleckenstein, J., Schmitz, N., Loeffler, M. and Ziepert, M. (2020). Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: a subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA). Oncol. Res. Treat., 43 (SUPPL 4). S. 61 - 62. BASEL: KARGER. ISSN 2296-5262
Voltin, C., Stockter, S., Baues, C., Fuchs, M., Dietlein, M., Mettler, J., Engert, A., Borchmann, P., Drzezga, A. and Kobe, C. (2017). Staging Patients with Hodgkin Lymphoma - Is Bone Marrow Biopsy Still Necessary in the Era of F-18-FDG PET? Eur. J. Nucl. Med. Mol. Imaging, 44. S. S244 - 2. NEW YORK: SPRINGER. ISSN 1619-7089
Voltin, C. -A., Goergen, H., Baues, C., Fuchs, M., Mettler, J., Kreissl, S., Oertl, J., Klaeser, B., Moccia, A., Drzezga, A., Engert, A., Borchmann, P., Dietlein, M. and Kobe, C. (2018). Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Ann. Oncol., 29 (9). S. 1926 - 1932. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Westin, J., Tam, C. S., Borchmann, P., Jaeger, U., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S., Bishop, M. R., Andreadis, C., Foley, S. R., Fleury, I, Ho, P. J., Mielke, S., Teshima, T., Schuster, S. J., Bachanova, V, Maziarz, R. T., Besien, K., V, Izutsu, K., Kersten, M. J., Wagner-Johnston, N. D., Kato, K., Corradini, P., Han, X., Tiwari, R., Eldjerou, L. K., Pacaud, L. B. and Salles, G. A. (2020). Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the JULIET trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 58 - 59. BASEL: KARGER. ISSN 2296-5262
von Tresckow, B., Kreissl, S., Haverkamp, H., Sasse, S., Diehl, V., Engert, A. and Borchmann, P. (2016). BEACOPP-ESCALATED FOLLOWED BY RADIOTHERAPY OF INITIAL BULK OR RESIDUAL DISEASE IN ADVANCED-STAGE HODGKIN LYMPHOMA: LONG-TERM FOLLOW-UP OF THE GHSG HD9 AND HD12 TRIALS. Haematologica, 101. S. 18 - 19. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078